Generic and biosimilar medicines save significantly more money for patients and plans than government price controls

WASHINGTON (October 7, 2025) — The Association for Accessible Medicines today commented on the Colorado Prescription Drug Affordability Board’s announcement this week to propose a price cap for a specific brand drug medication. The Colorado PDAB approved an upper payment limit of $600 for Enbrel. While there are several states with similar PDABs, the Colorado announcement was the first of its kind across the country.

“A competitive market is a better solution to lower costs than the government deciding what it’s going to pay,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “Generic and biosimilar medicines always save patients money and are the only facet of the health care system where prices continue to go down. Yet there is currently no biosimilar version of Enbrel available in the United States even though there are in other countries. The answer is reforms and regulations that stay true to the spirit of Hatch-Waxman, the law that empowered generic medicines, and BPCIA, the biosimilar equivalent.

###

2025 U.S. Generic & Biosimilar Medicines Savings Report:

https://accessiblemeds.org/resources/reports/2025-savings-report

For media inquiries, contact media@accessiblemeds.org.

About AAM

The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 12 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available biosimilarscouncil.org.